Fangzhou integrates DeepSeek-R1 into chronic disease management platform

Chinese digital health company Fangzhou has integrated the DeepSeek-R1 open-source LLM in an upgrade expected to enhance its online chronic disease management platform’s capabilities and operational efficiency. The upgrade aims to deliver more precise and personalised healthcare solutions for both patients and healthcare providers.

By deploying DeepSeek-R1’s advanced analytical and reasoning capabilities, Fangzhou— which specialises in tailored medical care and precision medicine solutions for chronic disease patients— can provide data-driven decision support and advanced functionality while maintaining full control over privacy and data security.

For patients, the platform will improve health management by analysing medical reports, test results, and other health data. These insights will enable healthcare providers to offer personalised medication guidance and post-diagnosis care plans.

For healthcare providers, Fangzhou’s DeepSeek-R1-powered “AI Assistant” can streamline prescription reviews and patient management, allowing its 217,000 doctors to focus on more critical medical tasks. The model’s data-driven logic also incorporates science-based decision support, aiding in diagnosis and optimised treatment plans.

Looking ahead to 2025, Fangzhou is focused on developing specialised “AI Agent” applications to further harness DeepSeek-R1’s powerful analytical reasoning capabilities. By extracting deeper insights from medical data, these AI-driven solutions aim to enhance the efficiency and precision of digital health innovations.